AstraZeneca
FDA rejects AstraZeneca diabetes combination
October 16, 2015Research and Development, Sales and Marketing AstraZeneca, FDA, NDA, dapagliflozin, saxagliptin
The FDA has declined to approve AstraZeneca’s New Drug Application (NDA) for the investigational fixed-dose combination of Onglyza and and …
AstraZeneca accused of tax avoidance in Dutch scheme
October 14, 2015AstraZeneca, finance, tax, tax avoidance
AstraZeneca is the latest international firm to be accused of corporation tax avoidance, after an investigation claimed the firm is …
AstraZeneca halts lung cancer trials amidst safety concerns
October 13, 2015Manufacturing and Production AZD9291, AstraZeneca, MEDI4736, NSCLC, drug safety, durvalumab, interstitial lung disease, lung cancer, non-small cell lung cancer
AstraZeneca is stopping two trials of a combination of two of its pipeline cancer treatments, after reports that the pairing …
AstraZeneca’s Moventig now available through NHS
October 9, 2015Medical Communications, Research and Development, Sales and Marketing AstraZeneca, moventig
AstraZeneca has announced that Moventig (naloxegol) has been made available for adult patients with opioid-induced constipation (OIC) in England and …
AstraZeneca and US Government collaborate to develop new antibiotics
September 17, 2015Research and Development AstraZeneca, Azactam, BARDA, Department of Health and Human Services, HHHS, avibactam, aztreonam
AstraZeneca has entered into a public-private partnership with the US Department of Health and Human Services to develop drugs to …
AstraZeneca scores positive real-world Forxiga data
September 16, 2015Research and Development AstraZeneca, EASD, European Association for the Study of Diabetes, Forxiga, dapagliflozin, exenatide, real world data, real world evidence
The real-world study of AstraZeneca’s diabetes drug Forxiga has found its use in UK patients primary care patients supports the …
AstraZeneca purchases former Amgen US facility
September 15, 2015Manufacturing and Production Amgen, AstraZeneca, US, biologics, manufacturing, production
AstraZeneca has bolstered its US presence with the purchase of a high-tech biologics manufacturing facility from pharma rival Amgen. The …
Medimmune and Cancer Research UK launch new drug discovery lab
September 11, 2015Research and Development AstraZeneca, Cambridge, Cancer, Cancer Research UK, MedImmune, R&D, george freeman
MedImmune and the UK’s biggest cancer charity have opened a new laboratory for joint cancer research.Research at the laboratory, which …
AstraZeneca lung cancer drug clears UK market access hurdle
September 4, 2015Sales and Marketing AZD9291, AstraZeneca, Early Access to Medicines Scheme, MHRA, NSCLC, eams, lung cancer, non-small cell lung cancer
Follow @Pharmafocus
AZ appoints Genentech’s Sean Bohen as chief medical officer
August 25, 2015Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, Briggs Morrison, Sean Bohen
AstraZeneca has appointed Dr Sean Bohen as executive vice president of global medicines development and chief medical officer.Dr Bohen will …
AstraZeneca and Peregrine in immuno-oncology collaboration
August 24, 2015Research and Development AstraZeneca, Cancer, MEDI4736, Peregrine, Peregrine Pharmaceuticals, bavituximab, durvalumab, immunoncology, immunotherapy, oncology, tumours
AstraZeneca and Peregrine Pharmaceuticals will collaborate on a clinical trial to test two of the companies’ cancer treatments. The Phase …
MedImmune and Inovio collaborate on cancer vaccine
August 11, 2015Manufacturing and Production, Research and Development AstraZeneca, HPV, Inovio, MedImmune, cancer vaccines, cervical cancer, oncology
MedImmune has entered into a license agreement and collaboration with Inovio, a biotechnology company developing DNA-based immunotherapies for cancer and …
MedImmune and Mirati to partner on lung cancer combo
August 6, 2015Research and Development AstraZeneca, Cancer, MedImmune, Mirati, Mirati Therapeutics, NSCLC, durvalumab, immuno-oncology, immunotherapy, lung cancer, mocetinostat
MedImmune is entering into an exclusive clinical trial collaboration with US-based Mirati Therapeutics to test a novel immuno-oncology combination in …
AstraZeneca buys rights to Heptares experimental cancer treatment
August 6, 2015Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, Cancer, HTL-1071, immuno-oncology
AstraZeneca has entered into a licensing agreement with Heptares for the global rights to the experimental cancer treatment HTL-1071. The …
NICE demands more evidence of Lynparza benefits
August 6, 2015Sales and Marketing AstraZeneca, NICE, lynparza, ovarian cancer
AstraZeneca must provide a “robust estimate of the cost effectiveness” of its ovarian cancer treatment Lynparza, or risk being rejected …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
